Skip to content

Clinical application and safety evaluation of intravenous lidocaine in painless EUS

Clinical application and safety evaluation of intravenous lidocaine in painless EUS

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086658
Enrollment
Unknown
Registered
2024-07-08
Start date
2024-07-10
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing painless EUS

Interventions

lidocaine group:Intravenous infusion of lidocaine to patients undergoing EUS with propofol
control group:Intravenous infusion of saline to patients undergoing EUS with propofol

Sponsors

Affiliated Cancer Hospital of Chongqing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old 2. ASA grading I-III 3. Body mass index: 18 kg/m2 = BMI = 30 kg/m2 4.STOP-Bang score = 5 5. No arrhythmia and atrioventricular block 6. Normal liver and kidney function 7. without OSAHS 8. Sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Severe organ dysfunction 2. patients who are allergic to lidocaine 3. Neurological disorders 4. Patients with severe alcoholism

Design outcomes

Primary

MeasureTime frame
the dosage of propofol ;

Secondary

MeasureTime frame
Perioperative complications (hypotension, asphyxia, hypoxia, sinus brady, arrhythmias, agitation);

Countries

China

Contacts

Public Contactwang tongxuan

Affiliated Cancer Hospital of Chongqing University

1049254220@qq.com+86 183 2331 7980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 24, 2026